The company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date.
Tiziana Life Sciences Ltd sold 7,040,000 ordinary shares to senior management and existing shareholders without a placement agent. Each share came with a warrant at $1.50.
The requirement was met on March 12, 2025 after a notice dated January 29, 2025. Nasdaq considers the matter closed.
Questions about Tiziana Life Sciences
Has Tiziana Life Sciences raised money recently?
Our latest story on this, dated Jan 16, 2026: "Tiziana Life Sciences closes $8.8 million registered direct offering at $1.25 per share". The story links the filing or release it is based on. Read the story.
Has Tiziana Life Sciences received a Nasdaq deficiency notice?
Our latest story on this, dated Apr 30, 2026: "Tiziana Life Sciences files late-filing notice for its 2025 annual report on Form 20-F". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Tiziana Life Sciences?
Tiziana Life Sciences Ltd trades under the ticker TLSA on NASDAQ.
Where is Tiziana Life Sciences listed?
Tiziana Life Sciences Ltd is listed on NASDAQ. Our directory also records these other listings: GETTEX:0RP; LS:A3C5SS; LSX:A3C5SS.
What is the SEC CIK of Tiziana Life Sciences?
The SEC Central Index Key (CIK) for Tiziana Life Sciences Ltd is 1723069. Its filings are on SEC EDGAR.
How many shares does Tiziana Life Sciences have outstanding?
120,507,401 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-01.
Which country or territory is Tiziana Life Sciences listed under?
Our directory records Tiziana Life Sciences Ltd under Bermuda.
What does Tiziana Life Sciences do?
Our directory classifies Tiziana Life Sciences Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Tiziana Life Sciences?
The ISIN recorded for Tiziana Life Sciences Ltd is BMG889121031.
Does aibio.space cover Tiziana Life Sciences?
aibio.space lists Tiziana Life Sciences Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Tiziana Life Sciences incorporated?
SEC records list its state or country of incorporation as D0.
What is the latest Tiziana Life Sciences (TLSA) stock news?
Our latest story on Tiziana Life Sciences, dated Apr 30, 2026: "Tiziana Life Sciences files late-filing notice for its 2025 annual report on Form 20-F". The company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date. Source.
Is Tiziana Life Sciences in financial distress?
Our latest distress story, dated Apr 30, 2026: "Tiziana Life Sciences files late-filing notice for its 2025 annual report on Form 20-F". The company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date. Source.
Is Tiziana Life Sciences a smaller reporting company?
SEC records list Tiziana Life Sciences Ltd's filer category as: Non-accelerated filer.
Where is Tiziana Life Sciences headquartered?
SEC records list its business address as 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON, ENGLAND, United Kingdom, SW1Y 4LB.
Investor discussion: Tiziana Life Sciences
Members talk about Tiziana Life Sciences (TLSA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Tiziana Life Sciences, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TLSA on TradingView.
SEC filings and registration
SEC name
Tiziana Life Sciences Ltd
CIK
1723069
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
TLSA (Nasdaq)
State or country of incorporation
D0
Fiscal year ends
December 31
Filer category
Non-accelerated filer
Business address
3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON, ENGLAND, United Kingdom, SW1Y 4LB
Phone
0044(0) 207-495-2379
Shares outstanding
120,507,401 as of 2025-12-31 (20-F filed 2026-05-01)
Former names
Tiziana Life Sciences plc
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Tiziana Life Sciences Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TLSA, recorded under Bermuda. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio